47.42
+0.44(+0.94%)
Currency In USD
| Previous Close | 46.98 |
| Open | 46.83 |
| Day High | 48.62 |
| Day Low | 46.74 |
| 52-Week High | 60.34 |
| 52-Week Low | 24.1 |
| Volume | 727,357 |
| Average Volume | 1.64M |
| Market Cap | 4.5B |
| PE | -10.47 |
| EPS | -4.53 |
| Moving Average 50 Days | 42.78 |
| Moving Average 200 Days | 34.51 |
| Change | 0.44 |
If you invested $1000 in Crinetics Pharmaceuticals, Inc. (CRNX) since IPO date, it would be worth $1,934.72 as of December 05, 2025 at a share price of $47.42. Whereas If you bought $1000 worth of Crinetics Pharmaceuticals, Inc. (CRNX) shares 5 years ago, it would be worth $3,426.3 as of December 05, 2025 at a share price of $47.42.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Crinetics Announces First Patient Dosed in Phase 1/2 Trial Evaluating CRN09682 for the Treatment of Neuroendocrine Tumors and Other Somatostatin Receptor 2-Expressing Tumors
GlobeNewswire Inc.
Dec 03, 2025 1:00 PM GMT
Initiation of trial marks milestone for Crinetics’ novel nonpeptide drug conjugate platformSAN DIEGO, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced the first patient has been dosed in the Phase 1/2
Crinetics Announces First Patient Randomized in Pivotal Phase 3 CAREFNDR Trial Evaluating Paltusotine in Carcinoid Syndrome
GlobeNewswire Inc.
Nov 20, 2025 9:05 PM GMT
CAREFNDR underscores the potential clinical value of paltusotine beyond acromegaly, and demonstrates progress in Crinetics’ commitment to addressing unmet needs in the neuroendocrine tumor community SAN DIEGO, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Cr
Crinetics Pharmaceuticals Announces November 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Nov 10, 2025 9:28 PM GMT
SAN DIEGO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on November 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purchase an agg